Structures by: Idris A.
Total: 8
N-(pyrazin-2-yl)aniline
C10H9N3
Acta Crystallographica Section E (2008) 64, 11 o2105
a=11.0644(3)Å b=7.8423(3)Å c=10.8907(3)Å
α=90.00° β=116.439(2)° γ=90.00°
2-(4-Chloroanilino)quinoxaline
C14H10ClN3
Acta Crystallographica Section E (2008) 64, 12 o2443
a=12.1550(10)Å b=11.2380(10)Å c=35.421(3)Å
α=90.00° β=90.00° γ=90.00°
4-Chloro-<i>N</i>-(2-pyridyl)aniline
C11H9ClN2
Acta Crystallographica Section E (2008) 64, 12 o2437
a=15.5096(4)Å b=7.5519(2)Å c=17.6846(4)Å
α=90.00° β=106.284(2)° γ=90.00°
Phenyl pyrazin-2-yl ether
C10H8N2O
Acta Crystallographica Section E (2009) 65, 1 o7
a=5.7040(10)Å b=8.557(2)Å c=17.595(4)Å
α=90.00° β=94.382(3)° γ=90.00°
<i>N</i>-(3-Methylphenyl)quinoxalin-2-amine monohydrate
C15H13N3,H2O
Acta Crystallographica Section E (2010) 66, 9 o2276
a=10.9002(8)Å b=11.1048(8)Å c=11.1715(8)Å
α=90° β=106.7800(10)° γ=90°
<i>N</i>-(Pyrazin-2-yl)-4-toluidine
C11H11N3
Acta Crystallographica Section E (2008) 64, 12 o2440
a=21.7179(7)Å b=7.5323(3)Å c=12.0073(5)Å
α=90.00° β=105.790(3)° γ=90.00°
4-Chloro-<i>N</i>-(pyrazin-2-yl)aniline
C10H8ClN3
Acta Crystallographica Section E (2009) 65, 1 o113
a=12.1257(3)Å b=3.79440(10)Å c=19.7242(5)Å
α=90.00° β=91.370(2)° γ=90.00°
<i>N</i>-(Quinoxalin-2-yl)-4-toluidine
C15H13N3
Acta Crystallographica Section E (2009) 65, 1 o93
a=12.2081(9)Å b=11.3720(9)Å c=35.097(3)Å
α=90.00° β=90.00° γ=90.00°